Related Experiment Video

Updated: Aug 14, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

Therapeutics in renal disease: the road ahead for antiproliferative targets

Peter J Nelson1, Stuart J Shankland

  • 1Division of Nephrology, New York University School of Medicine, New York, NY 10016, USA. nelsop02@popmail.med.nyu.edu

Nephron. Experimental Nephrology
|December 13, 2005
PubMed

Insights

Targeted therapies aim to preserve kidney function in proliferative renal diseases by inhibiting cell-cycle progression. Early trials show promise, but differences between nephrology and oncology targets require further research for optimal drug efficacy.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pharmacology

Background:

  • Molecular basis of renal disease is rapidly advancing.
  • NIH Roadmap promotes translating discoveries into treatments.
  • Proliferative renal diseases involve abnormal cell-cycle progression.

Purpose of the Study:

  • Review therapeutic strategies for preserving renal function in proliferative renal diseases.
  • Discuss targeted therapy by inhibiting mitogenic pathways.
  • Highlight differences between molecular nephrology and oncology therapeutic goals.

Main Methods:

  • Review of reductionist methodologies identifying antiproliferative molecular targets.
  • Analysis of preclinical testing of small-molecule drugs.
  • Examination of clinical trials for targeted renal therapies.

Main Results:

  • Several antiproliferative molecular targets have been identified.
  • Promising preclinical data exists for small-molecule drugs.
  • Clinical trials are underway for targeted renal therapies.

Conclusions:

  • Targeted therapy offers a promising strategy for proliferative renal diseases.
  • Differences in therapeutic goals between nephrology and oncology need clarification.
  • Systems research is crucial to accelerate the development of effective renal therapies.

More Related Videos

Intravascular Delivery of Biologics to the Rat Kidney07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...